ArticleBMC cancer2026
The impact of low skeletal muscle index and low muscle radiodensity on the prognosis of esophageal squamous cell carcinoma: a multi-center retrospective study in China (TIMES Study).
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of skeletal muscle mass and muscle quality in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) undergoing neoadjuvant chemoradiotherapy (NCRT) remains unclear. We investigated the association of low skeletal muscle index (SMI) and low skeletal muscle radiodensity (SMD, reflecting myosteatosis) with long-term survival.
methodsWe conducted a multicenter retrospective study including consecutive LA-ESCC patients treated between 2014 and 2023 at three tertiary hospitals. SMI and SMD were measured at the third lumbar vertebral level on preoperative CT images. Optimal cutoff values were determined using time-dependent receiver operating characteristic curve analysis. Overall survival (OS) was analyzed using Kaplan–Meier curves and Cox proportional hazards models. Sex-specific analyses were conducted to explore potential effect modification.
resultsA total of 420 patients were included, with a median follow-up of 39.1 months, the 5-year OS rate was 60%. Low SMI and low SMD were both significantly associated with worse OS. In multivariable analysis, low SMI (hazard ratio [HR] 2.23, 95% CI 1.17–4.24; P = 0.015) and low SMD (HR 2.41, 95% CI 1.36–4.26; P = 0.003) remained independent predictors of OS. Patients with concomitant low SMI and low SMD had the poorest survival(56.8% vs 60.8%, P = 0.037). Sex-stratified analysis demonstrated that myosteatosis remained an independent predictor of OS in male patients (HR 1.71, 95% CI 1.16–2.52; P = 0.007). Among men, 5-year OS was 47.1% in those with myosteatosis versus 63.7% in those without (HR 1.67, P = 0.015).
conclusionsBoth reduced muscle mass and impaired muscle quality are associated with adverse long-term outcomes in LA-ESCC patients undergoing NCRT and surgery. Myosteatosis, in particular, appears to confer a stronger prognostic impact in male patients. Assessment of skeletal muscle composition may improve risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.